Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–57.
Article
CAS
Google Scholar
Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–46.
Article
CAS
Google Scholar
Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015;16(2):141–51.
Article
CAS
Google Scholar
Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(11):1454–66.
Article
CAS
Google Scholar
Park K, Tan EH, O’Byrne K, Zhang L, Boyer M, Mok T, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016;17(5):577–89.
Article
CAS
Google Scholar
Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113–25.
Article
CAS
Google Scholar
Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3(75):75ra26.
Article
Google Scholar
Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376(7):629–40.
Article
CAS
Google Scholar
Oxnard GR, Hu Y, Mileham KF, Husain H, Costa DB, Tracy P, et al. Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to Osimertinib. JAMA Oncol. 2018;4(11):1527–34.
Article
Google Scholar
Larsen AK, Ouaret D, El Ouadrani K, Petitprez A. Targeting EGFR and VEGF(R) pathway crosstalk in tumor survival and angiogenesis. Pharmacol Ther. 2011;131(1):80–90.
Article
CAS
Google Scholar
Li H, Takayama K, Wang S, Shiraishi Y, Gotanda K, Harada T, et al. Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression. Cancer Chemother Pharmacol. 2014;74(6):1297–305.
Article
CAS
Google Scholar
Lai Y, Zhao Z, Zeng T, Liang X, Chen D, Duan X, et al. Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma. Cancer Cell Int. 2018;18:31.
Article
Google Scholar
Seto T, Kato T, Nishio M, Goto K, Atagi S, Hosomi Y, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 2014;15(11):1236–44.
Article
CAS
Google Scholar
Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2019;20(5):625–35.
Article
CAS
Google Scholar
Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(12):1655–69.
Article
CAS
Google Scholar
Huang YH, Hsu KH, Chin CS, Tseng JS, Yang TY, Chen KC, et al. The clinical outcomes of different first-line EGFR-TKIs plus Bevacizumab in advanced EGFR-mutant lung adenocarcinoma. Cancer Res Treat. 2022;54(2):434–44.
Hsu PC, Huang CY, Wang CC, Kuo SC, Chu CH, Tung PH, et al. The combination of Afatinib and Bevacizumab in untreated EGFR-mutated advanced lung adenocarcinoma: a multicenter observational study. Pharmaceuticals (Basel). 2020;13(11):331.
Article
CAS
Google Scholar
Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384(9944):665–73.
Article
CAS
Google Scholar
Kashiwabara K, Fujii S, Tsumura S, Sakamoto K, Semba H. Additional bevacizumab in EGFR-mutant lung adenocarcinoma patients who had oligo-progression after the failure of EGFR-TKI: a single-institute retrospective study. Cancer Treat Res Commun. 2020;22:100163.
Article
Google Scholar
Woodford RG, Zhou DD, Kok PS, Lord SJ, Friedlander M, Marschner IC, et al. The validity of progression-free survival 2 as a surrogate trial end point for overall survival. Cancer. 2022;128(7):1449–57.
Article
Google Scholar
Tsai JS, Su PL, Yang SC, Chang CC, Lin CY, Yen YT, et al. EGFR-TKI plus bevacizumab versus EGFR-TKI monotherapy for patients with EGFR mutation-positive advanced non-small cell lung cancer-A propensity score matching analysis. J Formos Med Assoc. 2021;120(9):1729–39.
Article
CAS
Google Scholar
Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009;27(8):1227–34.
Article
CAS
Google Scholar
Zeng L, Xiao L, Jiang W, Yang H, Hu D, Xia C, et al. Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with EGFR sensitive mutant non-small cell lung cancer in a Real world population. Lung Cancer. 2020;141:82–8.
Article
Google Scholar
Hong S, Gao F, Fu S, Wang Y, Fang W, Huang Y, et al. Concomitant genetic alterations with response to treatment and epidermal growth factor receptor tyrosine kinase inhibitors in patients with EGFR-mutant advanced non-small cell lung cancer. JAMA Oncol. 2018;4(5):739–42.
Article
Google Scholar
Yu Y, Wang Y, Wu L, Xu X, Zhou H, Wang Q, et al. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) combined with bevacizumab for advanced non-squamous non-small-cell lung cancer patients with gradual progression on EGFR-TKI treatment: a cohort study. Medicine (Baltimore). 2021;100(5):e23712.
Article
CAS
Google Scholar
Sa-Nguanraksa D, Chuangsuwanich T, Pongpruttipan T, O-Charoenrat P. High vascular endothelial growth factor gene expression predicts poor outcome in patients with non-luminal a breast cancer. Mol Clin Oncol. 2015;3(5):1103–8.
Article
CAS
Google Scholar
Lin C, Zhang Z, Xu Y, Wang R, Chen S, Gao J, et al. High tumor vascular endothelial growth factor expression is associated with poorer clinical outcomes in resected T3 gastric adenocarcinoma. Am J Clin Pathol. 2016;146(3):278–88.
Article
CAS
Google Scholar
Morgensztern D, Waqar S, Subramanian J, Trinkaus K, Govindan R. Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer. J Thorac Oncol. 2012;7(10):1485–9.
Article
Google Scholar
Hamed EA, El-Noweihi AM, Mohamed AZ, Mahmoud A. Vasoactive mediators (VEGF and TNF-alpha) in patients with malignant and tuberculous pleural effusions. Respirology. 2004;9(1):81–6.
Article
Google Scholar
Chen Y, Mathy NW, Lu H. The role of VEGF in the diagnosis and treatment of malignant pleural effusion in patients with nonsmall cell lung cancer (Review). Mol Med Rep. 2018;17(6):8019–30.
CAS
PubMed
PubMed Central
Google Scholar
Masago K, Fujimoto D, Fujita S, Hata A, Kaji R, Ohtsuka K, et al. Response to bevacizumab combination chemotherapy of malignant pleural effusions associated with non-squamous non-small-cell lung cancer. Mol Clin Oncol. 2015;3(2):415–9.
Article
Google Scholar
Jiang T, Li A, Su C, Li X, Zhao C, Ren S, et al. Addition of bevacizumab for malignant pleural effusion as the manifestation of acquired EGFR-TKI resistance in NSCLC patients. Oncotarget. 2017;8(37):62648–57.
Article
Google Scholar
Seo Y, Baba H, Fukuda T, Takashima M, Sugimachi K. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer. 2000;88(10):2239–45.
Article
CAS
Google Scholar
Ren Y, Dai C, Zheng H, Zhou F, She Y, Jiang G, et al. Prognostic effect of liver metastasis in lung cancer patients with distant metastasis. Oncotarget. 2016;7(33):53245–53.
Article
Google Scholar
Sato H, Nagashima H, Akiyama M, Ito T, Hashimoto T, Saikawa H, et al. Analysis of bevacizumab treatments and metastatic sites of lung cancer. Cancer Treat Res Commun. 2021;26:100290.
Article
Google Scholar
Riihimaki M, Hemminki A, Fallah M, Thomsen H, Sundquist K, Sundquist J, et al. Metastatic sites and survival in lung cancer. Lung Cancer. 2014;86(1):78–84.
Article
CAS
Google Scholar
Aldridge SE, Lennard TW, Williams JR, Birch MA. Vascular endothelial growth factor acts as an osteolytic factor in breast cancer metastases to bone. Br J Cancer. 2005;92(8):1531–7.
Article
CAS
Google Scholar
Iguchi H, Yokota M, Fukutomi M, Uchimura K, Yonemasu H, Hachitanda Y, et al. A possible role of VEGF in osteolytic bone metastasis of hepatocellular carcinoma. J Exp Clin Cancer Res. 2002;21(3):309–13.
CAS
PubMed
Google Scholar
Hu Y, Ren H, Yang L, Jin C, Wei Y. Effect of molecular targeted therapy combined with radiotherapy on the expression and prognostic value of COX-2 and VEGF in bone metastasis of lung cancer. J BUON. 2020;25(2):811–20.
PubMed
Google Scholar